Showing 9531-9540 of 20355 results for "".
- Whole Health Team Improved Pain Interference In VA Trialhttps://reachmd.com/news/whole-health-pain-interference-va/2487415/Key Takeaways The Whole Health arm was associated with greater improvement in 12-month pain interference than either comparator. Group cognitive behavioral therapy was not significantly different from usual care on the primary endpoint. Suicid
- Tumor-Informed ctDNA Stratifies Risk in Anal Squamous Cell Carcinomahttps://reachmd.com/news/tumor-informed-ctdna-stratifies-risk-in-anal-squamous-cell-carcinoma/2487405/Key Takeaways End-of-treatment ctDNA positivity was associated with worse 1-year overall survival, progression-free survival, and locoregional failure, including 96% versus 63% overall survival and 92% versus 44% progression-free survival for ctDNA-negative ver
- MenACYW-TT Coadministration Trial Reports Non-Inferior Immune Responseshttps://reachmd.com/news/menacyw-tt-coadministration-trial-reports-non-inferior-immune-responses/2487412/Key Takeaways Both co-primary non-inferiority endpoints were met at the prespecified 6-month and 12- to 15-month assessments. Routine pediatric vaccine responses were also non-inferior with MenACYW-TT coadministration. Reactogenicity and broad
- Thrive Trial Shows Increase in Home Health Referrals for Medicaid Patientshttps://reachmd.com/news/thrive-home-health-referrals-medicaid/2487391/Key Takeaways Trained discharge planners were more likely to refer eligible patients to home health services than planners who had not yet entered the intervention. Implementation ratings were uniformly high, with acceptability, appropriateness, and fe
- Maternal RSV Vaccination, Nirsevimab in Infants, and Sequential Administrationhttps://reachmd.com/news/maternal-rsv-infant-nirsevimab/2487394/Key Takeaways A prospective randomized phase 4 comparison examined maternal vaccination, infant nirsevimab, and sequential administration in enrolled mother-infant pairs. No related serious adverse events were seen in mothers or infants, and infant nir
- Buprenorphine After Ketamine for Suicidal Ideation in MDDhttps://reachmd.com/news/buprenorphine-ketamine-suicidal-ideation-mdd/2487395/Key Takeaways Greater improvement in SSI total score was observed with buprenorphine than with placebo after ketamine. Depression scores did not differ significantly between groups. No serious treatment-related adverse events were reported.
- Ultra-Processed Food Intake and Mortality in the PLCO Cohorthttps://reachmd.com/news/ultra-processed-food-intake-and-mortality-in-the-plco-cohort/2487360/Key Takeaways Higher ultra-processed food intake was associated with modestly higher all-cause mortality in this cohort. Higher risks were also observed for circulatory system, nervous system, and other-cause mortality, while cancer mortality was not a
- Linerixibat Improved Pruritus in Phase 3 PBC Trialhttps://reachmd.com/news/linerixibat-improved-pruritus-in-phase-3-pbc-trial/2487359/Key Takeaways Linerixibat was associated with greater pruritus improvement than placebo over 24 weeks. Gastrointestinal adverse events, especially diarrhea, were reported more often with linerixibat than with placebo. The randomized phase 3 co
- Technology-Based Dry Eye Interventions Rank Differently by Outcomehttps://reachmd.com/news/technology-based-dry-eye-interventions-rank-differently-by-outcome/2487377/Key Takeaways Different technologies led different short-term endpoints, with TearCare plus meibomian gland expression topping gland secretion and IPL alone ranking highest for symptom relief. IPL-based approaches were associated with better tear break
- SCRATCH-AD: Rapid Itch Reduction, Biomarker Improvements with Ruxolitinibhttps://reachmd.com/news/scratch-ad-rapid-itch-reduction-biomarker-improvements-with-ruxolitinib/2487381/Patients with atopic dermatitis (AD) treated with ruxolitinib 1.5% cream experienced rapid and sustained reductions in itch alongside improvements in disease-associated biomarkers, according to findings from the SCRATCH-AD study. The open-label SCRATCH-AD trial (NCT04839380) evaluated the